Last Updated: September 28 2022

Kava is a herb that has traditionally been drunk as a hypnotic and anxiety reducer. It has been shown effective in reducing anxiety, sometimes at a potency similar to pharmaceuticals; may be a cognitive enhancer, but not completely safe.

Kava is most often used for

What else is Kava known as?
Note that Kava is also known as:
  • Piper methysticum
  • Kava Pepper
  • Ava Pepper
  • Kava Kava
  • Intoxicating Pepper
  • Awa
  • rauschpfeffer
  • sakau
  • tonga
  • wurzelstock
  • yangona
Dosage information

When supplementing Kava, initially an extract known as WS1490 should be sought out. 300mg of this extract daily (in three divided doses of 100mg) appears to be reliable and effective for the treatment of anxiety and other cognitive issues. Doses of up to 800mg of the WS1490 extract have been tolerated for short periods of time.

Otherwise, supplementation of any product conferring 250mg collective kavalactones (the active ingredients) is used.

Although it is usually taken at multiple times throughout the day with meals, if a single dose per day is being used it tends to be used prior to sleep.

Join our supplement information course

Examine Database: Kava
What works and what doesn't?

Unlock the full potential of Examine

Get started

Don't miss out on the latest research

1.^Ulbricht C, Basch E, Boon H, Ernst E, Hammerness P, Sollars D, Tsourounis C, Woods J, Bent SSafety review of kava (Piper methysticum) by the Natural Standard Research CollaborationExpert Opin Drug Saf.(2005 Jul)
2.^Singh YNKava: an overviewJ Ethnopharmacol.(1992 Aug)
3.^Mathews JD, Riley MD, Fejo L, Munoz E, Milns NR, Gardner ID, Powers JR, Ganygulpa E, Gununuwawuy BJEffects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal communityMed J Aust.(1988 Jun 6)
4.^Schelosky L, Raffauf C, Jendroska K, Poewe WKava and dopamine antagonismJ Neurol Neurosurg Psychiatry.(1995 May)
7.^Clayton NP, Yoshizawa K, Kissling GE, Burka LT, Chan PC, Nyska AImmunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extractExp Toxicol Pathol.(2007 Jan)
8.^Baum SS, Hill R, Rommelspacher HEffect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of ratsProg Neuropsychopharmacol Biol Psychiatry.(1998 Oct)
9.^Olsen LR, Grillo MP, Skonberg CConstituents in kava extracts potentially involved in hepatotoxicity: a reviewChem Res Toxicol.(2011 Jul 18)
10.^Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CSKava lactones and the kava-kava controversyPhytochemistry.(2003 Oct)
12.^Garrett KM, Basmadjian G, Khan IA, Schaneberg BT, Seale TWExtracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in micePsychopharmacology (Berl).(2003 Oct)
13.^Keledjian J, Duffield PH, Jamieson DD, Lidgard RO, Duffield AMUptake into mouse brain of four compounds present in the psychoactive beverage kavaJ Pharm Sci.(1988 Dec)
15.^Duffield AM, Jamieson DD, Lidgard RO, Duffield PH, Bourne DJIdentification of some human urinary metabolites of the intoxicating beverage kavaJ Chromatogr.(1989 Jul 28)
16.^Rasmussen AK, Scheline RR, Solheim E, Hänsel RMetabolism of some kava pyrones in the ratXenobiotica.(1979 Jan)
19.^Davies LP, Drew CA, Duffield P, Johnston GA, Jamieson DDKava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brainPharmacol Toxicol.(1992 Aug)
22.^Dinh LD, Simmen U, Bueter KB, Bueter B, Lundstrom K, Schaffner WInteraction of various Piper methysticum cultivars with CNS receptors in vitroPlanta Med.(2001 Jun)
29.^Pittler MH, Ernst EKava extract for treating anxietyCochrane Database Syst Rev.(2003)
31.^Connor KM, Payne V, Davidson JRKava in generalized anxiety disorder: three placebo-controlled trialsInt Clin Psychopharmacol.(2006 Sep)
32.^Jacobs BP, Bent S, Tice JA, Blackwell T, Cummings SRAn internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomniaMedicine (Baltimore).(2005 Jul)
33.^Cairney S, Clough AR, Maruff P, Collie A, Currie BJ, Currie JSaccade and cognitive function in chronic kava usersNeuropsychopharmacology.(2003 Feb)
34.^Cairney S, Maruff P, Clough AR, Collie A, Currie J, Currie BJSaccade and cognitive impairment associated with kava intoxicationHum Psychopharmacol.(2003 Oct)
35.^Spillane PK, Fisher DA, Currie BJNeurological manifestations of kava intoxicationMed J Aust.(1997 Aug 4)
36.^Robinson V, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW; Cosmetic Ingredient Review Expert Panel, Andersen FAFinal report on the safety assessment of Piper methysticum leaf/root/stem extract and Piper methysticum root extractInt J Toxicol.(2009 Nov-Dec)
39.^Jamieson DD, Duffield PHPositive interaction of ethanol and kava resin in miceClin Exp Pharmacol Physiol.(1990 Jul)
40.^Mathews JM, Etheridge AS, Valentine JL, Black SR, Coleman DP, Patel P, So J, Burka LTPharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitroDrug Metab Dispos.(2005 Oct)
41.^Schulze J, Raasch W, Siegers CPToxicity of kava pyrones, drug safety and precautions--a case studyPhytomedicine.(2003)
43.^Clouatre DLKava kava: examining new reports of toxicityToxicol Lett.(2004 Apr 15)
44.^Russmann S, Lauterburg BH, Helbling AKava hepatotoxicityAnn Intern Med.(2001 Jul 3)
45.^Humberston CL, Akhtar J, Krenzelok EPAcute hepatitis induced by kava kavaJ Toxicol Clin Toxicol.(2003)
46.^Gow PJ, Connelly NJ, Hill RL, Crowley P, Angus PWFatal fulminant hepatic failure induced by a natural therapy containing kavaMed J Aust.(2003 May 5)
47.^Sorrentino L, Capasso A, Schmidt MSafety of ethanolic kava extract: Results of a study of chronic toxicity in ratsPhytomedicine.(2006 Sep)
48.^Singh YN, Devkota AKAqueous kava extracts do not affect liver function tests in ratsPlanta Med.(2003 Jun)
49.^Clough AR, Jacups SP, Wang Z, Burns CB, Bailie RS, Cairney SJ, Collie A, Guyula T, McDonald SP, Currie BJHealth effects of kava use in an eastern Arnhem Land Aboriginal communityIntern Med J.(2003 Aug)
50.^Guro-Razuman S, Anand P, Hu Q, Mir RDermatomyositis-like illness following kava-kava ingestionJ Clin Rheumatol.(1999 Dec)
51.^Norton SA, Ruze PKava dermopathyJ Am Acad Dermatol.(1994 Jul)
53.^Ernst EAdverse effects of herbal drugs in dermatologyBr J Dermatol.(2000 Nov)
54.^Mathews JM, Etheridge AS, Black SRInhibition of human cytochrome P450 activities by kava extract and kavalactonesDrug Metab Dispos.(2002 Nov)
56.^Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet LZInhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava)Planta Med.(2002 Dec)
57.^Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong YSupplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivoClin Pharmacol Ther.(2008 Jan)
60.^Hsu SY, Lin MH, Lin LC, Chou CJToxicologic studies of dihydro-5,6-dehydrokawain and 5,6-dehydrokawainPlanta Med.(1994 Feb)